progressive supranuclear palsy

This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.

Spinraza lifts Biogen ahead of Alzheimer’s data

enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.

Celgene bulks up pipeline again with $2.1bn Prothena deal

The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);
AbbVie takes anti-tau drug into phase II for Alzheimer's

drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to
AbbVie and C2N take tau antibody into clinic

AbbVie and C2N take tau antibody into clinic. Treatment being assessed for a progressive neurodegenerative disorder. ... The first-in-class therapy - called C2N-8E12 or ABBV-8E12 - is being tested in patients with the rare neurodegenerative disorder
BMS buys Alzheimer's player iPierian in $725m deal

IPN007 is being developed in the first instance for progressive supranuclear palsy (PSP), a serious neurodegenerative disorder that progresses much more quickly than Alzheimer's but is also characterised by tau
CNS drug wins orphan status

CNS drug wins orphan status. Drug-development company Mithridion has won orphan status from the US Food and Drug Administration for a potential treatment for brain disease progressive supranuclear palsy. ... The clinical-stage drug-development company

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Deal Watch - May 2017

BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for progressive supranuclear palsy.
Deal Watch table for April 2014

750. iPerian/ BMS. Acquisition. CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Add my company

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?: What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma: Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies: Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...